1. Home
  2. MLYS vs USNA Comparison

MLYS vs USNA Comparison

Compare MLYS & USNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$25.93

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo USANA Health Sciences Inc.

USNA

USANA Health Sciences Inc.

HOLD

Current Price

$14.54

Market Cap

397.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
USNA
Founded
2019
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
397.1M
IPO Year
2023
1996

Fundamental Metrics

Financial Performance
Metric
MLYS
USNA
Price
$25.93
$14.54
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
★ $48.67
N/A
AVG Volume (30 Days)
★ 1.2M
169.8K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 37.43
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $1,060,902,000.00
Revenue This Year
N/A
$3.90
Revenue Next Year
N/A
$6.21
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.30
$12.57
52 Week High
$47.65
$28.52

Technical Indicators

Market Signals
Indicator
MLYS
USNA
Relative Strength Index (RSI) 41.89 46.71
Support Level $25.56 $12.57
Resistance Level $31.36 $15.75
Average True Range (ATR) 1.66 0.52
MACD -0.32 0.11
Stochastic Oscillator 10.32 33.14

Price Performance

Historical Comparison
MLYS
USNA

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About USNA USANA Health Sciences Inc.

Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).

Share on Social Networks: